The personalized approach to the prevention of cardiovascular diseases

Prof. Korzh O.M.

Kharkiv National Medical University

The article presents a number of major updates on the assessment of the risk of cardiovascular complications and the principles of preventive intervention based on the materials of the analyzed clinical recommendations. Previous European guidelines focused on risk stratification and prevention of risk factors, whereas the updated European Society of Cardiology document places great emphasis on personalization and stepwise intervention in clinical practice. When developing a prevention strategy, it is recommended to pay attention not only to gender and age indicators, but also to geographic and ethnic factors. A personalized approach to prevention using a cardiovascular risk score and stepwise selection of treatment are more complex than a general prevention strategy, but they reflect the diversity of patients and their characteristics in clinical practice.

Keywords: prevention, cardiovascular diseases, personalized approach, risk factors.

Download.PDF (ukr)


Корж, О.М. Персоналізований підхід до профілактики серцево-судинних захворювань // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2023. – № 1. – С. 102-106. doi: 10.15407/internalmed2023.01.102

Korzh OM. Personalizovanyi pidkhid do profilaktyky sertsevo-sudynnykh zakhvoriuvan [The personalized approach to the prevention of cardiovascular diseases]. Shidnoevr. z. vnutr. simejnoi med. 2023;1:102-106. Ukrainian. doi: 10.15407/internalmed2023.01.102


  1. Halle M, Davos C, Dendale P, Papadakis M, Pfaff C, Kränkel N. Future of preventive cardiology: EAPC vision 2020–22. European Journal of Preventive Cardiology. 2021;28(4):356-358.
  2. Gielen S. The new EAPC core curriculum for preventive cardiology: the keystone of the EAPC transformation. European Journal of Preventive Cardiology. 2021;29(1):246-250.
  3. Haniffa M, Taylor D, Linnarsson S, Aronow B, Bader G, Camara P, Camp J, Chédotal A, Copp A, Etchevers H, Giacobini P, Gottgens B, Guo G, Hupalowska A, James K, Kirby E, Kriegstein A, Lundeberg J, Marioni J, Meyer K, Niakan K, Nilsson M, Olabi B, Pe’er D, Regev A, Rood J, Rozenblatt-Rosen O, Satija R, Teichmann S, Treutlein B, Vento-Tormo R, Webb S. Human Developmental Cell Atlas: milestones achieved and the roadmap ahead. 2020;:.
  4. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. PMID: 34458905.
  5. Conroy R. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal. 2003;24(11):987-1003.
  6. Zeng L, Talukdar H, Koplev S, Giannarelli C, Ivert T, Gan L, Ruusalepp A, Schadt E, Kovacic J, Lusis A, Michoel T, Schunkert H, Björkegren J. Contribution of Gene Regulatory Networks to Heritability of Coronary Artery Disease. Journal of the American College of Cardiology. 2019;73(23):2946-2957.
  7. Münzel T, Sørensen M, Lelieveld J, Hahad O, Al-Kindi S, Nieuwenhuijsen M, Giles-Corti B, Daiber A, Rajagopalan S. Heart healthy cities: genetics loads the gun but the environment pulls the trigger. European Heart Journal. 2021;42(25):2422-2438.
  8. Musunuru K, Kathiresan S. Genetics of Common, Complex Coronary Artery Disease. Cell. 2019;177(1):132-145.
  9. Armenian S, Xu L, Ky B, Sun C, Farol L, Pal S, Douglas P, Bhatia S, Chao C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. Journal of Clinical Oncology. 2016;34(10):1122-1130.
  10. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13. PMID: 32061315; PMCID: PMC7049905.
  11. Chen W, Thomas J, Sadatsafavi M, FitzGerald J. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. The Lancet Respiratory Medicine. 2015;3(8):631-639.
  12. Kurth T, Winter A, Eliassen A, Dushkes R, Mukamal K, Rimm E, Willett W, Manson J, Rexrode K. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;:i2610.
  13. Jha M, Qamar A, Vaduganathan M, Charney D, Murrough J. Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology. 2019;73(14):1827-1845.
  14. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64:100–110. Doi: 10.1016/j.jacc.2014.03.047
  15. Jakicic J, Kraus W, Powell K, Campbell W, Janz K, Troiano R, Sprow K, Torres A, Piercy K. 2018 Physical Activity Guidelines Advisory Committee. Association between Bout Duration of Physical Activity and Health: Systematic Review. Med Sci Sports Exerc. 2019;51:1213–1219. Doi: 10.1249/MSS.0000000000001933.
  16. Guasch-Ferré M, Satija A, Blondin S, Janiszewski M, Emlen E, O’Connor L, Campbell W, Hu F, Willett W, Stampfer M. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. Circulation. 2019;139(15):1828-1845.
  17. Anthonisen N, Skeans M, Wise R, Manfreda J, Kanner R, Connett J. The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality. Annals of Internal Medicine. 2005;142(4):233.
  18. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen T, Tonkin A, Davis B, Sleight P, Franzosi M, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. Doi: 10.1016/S0140–6736 (10) 61350–5.
  19. Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-967.
  20. Marx N, Davies M, Grant P, Mathieu C, Petrie J, Cosentino F, Buse J. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. The Lancet Diabetes & Endocrinology. 2021;9(1):46-52.
  21. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey R, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh B, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud  F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax J, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477. Doi: 10.1093/eurheartj/ehz425.
  22. Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini G. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. The Lancet. 2020;395(10235):1487-1495.
  23. Oldridge N, Höfer S, McGee H, Saner H. Evaluation of health-related quality of life in cardiovascular research: a call for action. European Journal of Preventive Cardiology. 2021;29(2):e79-e81.